Clinical Trials Logo

Recurrent High-grade Glioma clinical trials

View clinical trials related to Recurrent High-grade Glioma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06463184 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

Researchers will investigate the ability of Xevinapant to cross the blood-brain barrier and exert anti-tumor effects on rHGG through activation of apoptosis. We hypothesize that oral administration of Xevinapant has acceptable safety and tolerability in patients with recurrent HGG and demonstrate pharmacokinetic and pharmacodynamic effects in HGG tumors. To that end, we will engage in a phase I "window of opportunity" translational clinical trial in patients undergoing a clinically-indicated craniotomy for resection of their recurrent tumors to evaluate the impact of treatment on rHGG.

NCT ID: NCT06126744 Not yet recruiting - Clinical trials for Recurrent High Grade Glioma

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

PuMP
Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhanced delivery (CED) in patients with recurrent high-grade glioma. Once the safety and maximum tolerated dose (MTD) is established in the dose escalation portion of the trial, a dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with isocitrate dehydrogenase (IDH) wildtype recurrent glioblastoma (GBM) will evaluate preliminary efficacy of the study drug.

NCT ID: NCT02416999 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Start date: May 2015
Phase: N/A
Study type: Interventional

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

NCT ID: NCT02333513 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Start date: February 2015
Phase: N/A
Study type: Interventional

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.